Lupin gets EIR from USFDA for Pithampur facility
New Delhi: Drug firm Lupin said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur, Unit 1 manufacturing facility in Madhya Pradesh.
The inspection was conducted in July 2017, it said in a BSE filing.
USFDA gives EIR on the closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
In November last, Lupin had received a warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd